This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
WATCH ON-DEMAND: Sessions 5-8keyboard_arrow_right

WATCH ON-DEMAND: Sessions 5-8

keyboard_arrow_leftSearch & Filter
search

WATCH ON-DEMAND: Sessions 5-8

search
These ON-DEMAND Presentations Will Be Available To View 24 Hours a Day At Your Convenience for 30 Days. Watch The Talks Below at Your Convenience Then Join the Live Speaker Q&A/Discussions on August 24-27 - See WATCH LIVE Tab for Schedule
On Demand
Session 5: Bispecific Antibodies: New Approaches and Case Studies
SESSION CHAIR: Mark Your Calendar for Wednesday, August 26, 15:45-16:30 for the Live Speaker Q&A/Panel Discussion with the Speakers in this Session - Check the "Watch Live" Session Tab for Details. We Recommend That You Watch These On-Demand Presentations Prior to the Live Q&A/Panel
  • Kerry Chester, PhD - Professor of Molecular Medicine, UCL Cancer Institute
  • Aran Labrijn, PhD - Principal Scientist, Antibody Research and Technology, Genmab
On Demand
Session 6: Modifying Fc Interactions to Enhance Antibody Therapies
SESSION CHAIR: Mark Your Calendar for Wednesday, August 26, 11:15-12:00 for the Live Speaker Q&A/Panel Discussion with the Speakers in this Session - Check the "Watch Live" Session Tab for Details. We Recommend That You Watch These On-Demand Presentations Prior to the Live Q&A/Panel
  • Sally Ward, PhD - Professor, University of Southampton and Texas A&M University Health Science Center
On Demand
Session 7: Cell Engagers for the Innate Immune System
SESSION CHAIR: Mark Your Calendar for Thursday, August 27, 11:15-12:00 for the Live Speaker Q&A/Panel Discussion with the Speakers in this Session - Check the "Watch Live" Session Tab for Details. We Recommend That You Watch These On-Demand Presentations Prior to the Live Q&A/Panel
  • Jeanette Leusen, PhD - Associate Professor, Head Immunotherapy Group, University Medical Center Utrecht
  • Matthias Peipp, PhD - Professor and Head of Research, Christian-Albrechts-University Kiel
On Demand
Session 8: Potentiating Antibodies through Conjugation
SESSION CHAIR: Mark Your Calendar for Thursday, August 27, 15:45-16:30 for the Live Speaker Q&A/Panel Discussion with the Speakers in this Session - Check the "Watch Live" Session Tab for Details. We Recommend That You Watch These On-Demand Presentations Prior to the Live Q&A/Panel
  • Christoph Rader - Professor, Department of Immunology and Microbiology, The Scripps Research Institute
On Demand
Session 5: Bispecific Antibodies: New Approaches and Case Studies
Targeting the IgA Fc Receptor in Cancer Therapy
  • Marjolein van Egmond - Professor of Oncology and Inflammation, Amsterdam University Medical Center
On Demand
Session 6: Modifying Fc Interactions to Enhance Antibody Therapies
Engineering IgG2 and IgG4 Fc Chains Creates Novel and Potent Effector mAbs
  • Mark Hogarth, PhD - Professor and Burnet Senior Principal Research Fellow, Burnet Institute
On Demand
Session 7: Cell Engagers for the Innate Immune System
PD1-IL2v, A Novel PD-1 Targeted Immunocytokine for Cancer Immunotherapy
  • Christian Klein, PhD - Head Oncology Programs, Roche Innovation Center Zurich
On Demand
Session 8: Potentiating Antibodies through Conjugation
Chemoenzymatic Strategies to Generate High-DAR ADCs
  • Harald Kolmar, PhD - Professor and Head of Applied Biochemistry, TU Darmstadt
On Demand
Session 5: Bispecific Antibodies: New Approaches and Case Studies
GABs: Bispecific Engagers to Recruit T cells to Gamma Delta Targets
  • Jürgen Kuball, PhD - Professor, UMC Utrecht Cancer Center
On Demand
Session 6: Modifying Fc Interactions to Enhance Antibody Therapies
Regulation of NK Cell-mediated ADCC: Implications for Therapeutic Antibodies
  • Gestur Vidarsson, PhD - Head of Immunoglobulin Research/PI, Experimental Immunohematology, Sanquin Research
On Demand
Session 7: Cell Engagers for the Innate Immune System
Development of a Next Generation Anti-Cancer Immunotherapy: A Humanized anti-BTN3A Antibody that Activates V9V2 T cells
  • Rene Hoet, PhD - Chief Scientific Officer, Imcheck Therapeutics
On Demand
Session 8: Potentiating Antibodies through Conjugation
Clinical Stage GlycoConnect™ Technology based on Glycan Remodeling-Conjugation as a Powerful Platform for ADC and Bispecific Antibody Generation
  • Floris van Delft, PhD - Founder and Chief Scientific Officer, SynAffix BV
On Demand
Session 5: Bispecific Antibodies: New Approaches and Case Studies
Bispecific γδ-T cell Engagers for the Treatment of Cancer
  • Paul Parren, PhD - Professor, Leiden University Medical Center and EVP, R&D, Lava Therapeutics
On Demand
Session 6: Modifying Fc Interactions to Enhance Antibody Therapies
Equilibriums in Antibody Hexamerization: The Unpredicted Path to Product Design
  • Frank Beurskens, PhD - Principal Scientist, Genmab
On Demand
Session 7: Cell Engagers for the Innate Immune System
Novel NK Cell Engaging Formats Triggering NKp46
  • Laurent Gauthier, PhD - Senior Director, Innate Pharma Research Laboratory, Innate Pharma
On Demand
Session 8: Potentiating Antibodies through Conjugation
IlluminoxTM - A Novel, Tumor-targeted Treatment Platform that Ignites Local and Systemic Anti-cancer Immune Responses through Selective Cancer and Immunosuppressive Cell Destruction.
  • Jerry Fong, PhD - Associate Director, Cancer Biology and Pharmacology, Rakuten Medical
On Demand
Session 5: Bispecific Antibodies: New Approaches and Case Studies
A Biological Rationale for Toxicity Mitigation with CD3 Bispecifics
  • Teemu Junttila, PhD - Principal Scientist, Translational Oncology, Genentech
On Demand
Session 6: Modifying Fc Interactions to Enhance Antibody Therapies
Efgartigimod, A Novel FcRn Antagonist, for the Treatment of Patients with Severe Autoimmune Diseases
  • Hans de Haard, PhD - Chief Scientific Officer, Argenx
On Demand
Session 7: Cell Engagers for the Innate Immune System
Organ Specific Pathways of Cytotoxic Antibody Activity
  • Anja Lux, Ph.D. - Postdoctoral Researcher, University of Erlangen-Nuremberg, Germany
On Demand
Session 8: Potentiating Antibodies through Conjugation
Antibody-mediated Intracellular Delivery of Nucleic acids: Targeted Plasmid-chromatin
  • Ulrich Brinkmann, Ph.D. - Expert Scientist, Large Molecule Research, Pharma Research & Early Development, Roche Innovation Center, Munich
On Demand
Session 5: Bispecific Antibodies: New Approaches and Case Studies
The Distinct Binding Footprints of Bispecific T cell Receptors (TCR) and TCR-mimic Antibodies Underpin pHLA Selectivity
  • David Cole, PhD - Collaboration Research Group Leader, Immunocore
On Demand
Session 6: Modifying Fc Interactions to Enhance Antibody Therapies
Brain Shuttle Antibodies
  • Felix Weber - Laboratory Head Immunosafety, Roche
On Demand
Session 7: Cell Engagers for the Innate Immune System
Targeting SIRPa
  • Timo van den Berg, PhD - Head Department of Blood Cell Research, Sanquin Research
On Demand
Session 8: Potentiating Antibodies through Conjugation
Generation and Validation of Structurally Defined Antibody-siRNA Conjugates
  • Christoph Rader - Professor, Department of Immunology and Microbiology, The Scripps Research Institute
On Demand
Session 5: Bispecific Antibodies: New Approaches and Case Studies
Novel Ways to Activate and Target NK Cells with Tri-specific Killer Engagers (TriKETM) to Treat Cancer
  • Jeffrey Miller, MD - Professor of Medicine, University of Minnesota
WATCH ON-DEMAND: Sessions 1-4
NextWATCH ON-DEMAND: Scientific Briefings

Get the latest news.
As it happens

Sign up to get the latest on the agenda and speakers.
Filter
Streams
Choose Day